S&P 500   4,216.55 (+0.26%)
DOW   33,030.60 (-0.19%)
QQQ   350.36 (+0.56%)
AAPL   177.65 (+1.27%)
MSFT   331.37 (-0.46%)
META   265.04 (+1.14%)
GOOGL   122.51 (-1.69%)
AMZN   120.95 (+0.70%)
TSLA   198.15 (+2.58%)
NVDA   407.11 (+4.53%)
NIO   7.64 (-0.78%)
BABA   79.28 (-2.09%)
AMD   123.68 (-2.64%)
T   15.53 (+0.19%)
F   12.53 (+3.64%)
MU   72.09 (-2.49%)
CGC   0.86 (-1.44%)
GE   101.06 (-1.64%)
DIS   87.90 (-0.44%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   60.26 (+0.07%)
NFLX   386.96 (+2.13%)
S&P 500   4,216.55 (+0.26%)
DOW   33,030.60 (-0.19%)
QQQ   350.36 (+0.56%)
AAPL   177.65 (+1.27%)
MSFT   331.37 (-0.46%)
META   265.04 (+1.14%)
GOOGL   122.51 (-1.69%)
AMZN   120.95 (+0.70%)
TSLA   198.15 (+2.58%)
NVDA   407.11 (+4.53%)
NIO   7.64 (-0.78%)
BABA   79.28 (-2.09%)
AMD   123.68 (-2.64%)
T   15.53 (+0.19%)
F   12.53 (+3.64%)
MU   72.09 (-2.49%)
CGC   0.86 (-1.44%)
GE   101.06 (-1.64%)
DIS   87.90 (-0.44%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   60.26 (+0.07%)
NFLX   386.96 (+2.13%)
S&P 500   4,216.55 (+0.26%)
DOW   33,030.60 (-0.19%)
QQQ   350.36 (+0.56%)
AAPL   177.65 (+1.27%)
MSFT   331.37 (-0.46%)
META   265.04 (+1.14%)
GOOGL   122.51 (-1.69%)
AMZN   120.95 (+0.70%)
TSLA   198.15 (+2.58%)
NVDA   407.11 (+4.53%)
NIO   7.64 (-0.78%)
BABA   79.28 (-2.09%)
AMD   123.68 (-2.64%)
T   15.53 (+0.19%)
F   12.53 (+3.64%)
MU   72.09 (-2.49%)
CGC   0.86 (-1.44%)
GE   101.06 (-1.64%)
DIS   87.90 (-0.44%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   60.26 (+0.07%)
NFLX   386.96 (+2.13%)
S&P 500   4,216.55 (+0.26%)
DOW   33,030.60 (-0.19%)
QQQ   350.36 (+0.56%)
AAPL   177.65 (+1.27%)
MSFT   331.37 (-0.46%)
META   265.04 (+1.14%)
GOOGL   122.51 (-1.69%)
AMZN   120.95 (+0.70%)
TSLA   198.15 (+2.58%)
NVDA   407.11 (+4.53%)
NIO   7.64 (-0.78%)
BABA   79.28 (-2.09%)
AMD   123.68 (-2.64%)
T   15.53 (+0.19%)
F   12.53 (+3.64%)
MU   72.09 (-2.49%)
CGC   0.86 (-1.44%)
GE   101.06 (-1.64%)
DIS   87.90 (-0.44%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   60.26 (+0.07%)
NFLX   386.96 (+2.13%)
NASDAQ:SPRO

Spero Therapeutics (SPRO) Earnings Date, Estimates & Call Transcripts

$1.79
+0.02 (+1.13%)
(As of 10:07 AM ET)
Compare
Today's Range
$1.79
▼
$1.86
50-Day Range
$1.35
▼
$1.95
52-Week Range
$0.68
▼
$3.18
Volume
67,927 shs
Average Volume
478,899 shs
Market Capitalization
$94.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 9Estimated
Actual EPS
(Mar. 30)
$0.55 Beat By $0.95
Consensus EPS
(Mar. 30)
-$0.40
Last Year's Q1 EPS
(3/31/2022)
-$0.90
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

SPRO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SPRO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Spero Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($0.43)($0.43)($0.43)
Q2 20231($0.43)($0.43)($0.43)
Q3 20231($0.43)($0.43)($0.43)
Q4 20231$0.56$0.56$0.56
FY 20234($0.73)($0.73)($0.73)
Q1 20241($0.37)($0.37)($0.37)
Q2 20241($0.39)($0.39)($0.39)
Q3 20241($0.39)($0.39)($0.39)
Q4 20241$0.59$0.59$0.59
FY 20244($0.56)($0.56)($0.56)

SPRO Earnings Date and Information

Spero Therapeutics last announced its earnings data on March 30th, 2023. The reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.95. The firm had revenue of $47.44 million for the quarter, compared to the consensus estimate of $1.60 million. Spero Therapeutics has generated ($0.90) earnings per share over the last year (($0.90) diluted earnings per share). Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.05) to ($1.00) per share. Spero Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 9th, 2023 based off prior year's report dates.

Spero Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/9/2023
(Estimated)		        
3/30/2023Q4 2022($0.40)$0.55+$0.95$0.55$1.60 million$47.44 million
11/14/2022Q3 2022($0.34)($0.33)+$0.01($0.33)$6.75 million$2.01 million
8/10/2022Q2 2022($0.88)($0.87)+$0.01($0.87)$2.30 million$1.99 million
5/16/2022Q1 2022($0.87)($1.01)($0.14)($1.01)$2.85 million$2.07 million    
3/31/2022Q4 2021($0.80)($0.90)($0.10)($0.90)$2.90 million$2.74 million    
11/10/20219/30/2021($0.66)($0.70)($0.04)($0.70)$3.00 million$3.06 million    
8/5/20216/30/2021($0.77)($0.63)+$0.14($0.63)$2.55 million$5.15 million  
5/6/20213/31/2021($0.61)($0.66)($0.05)($0.66)$2.71 million$7.30 million  
3/11/202112/31/2020($0.77)($0.68)+$0.09($0.68)$3.25 million$1.91 million  
11/5/20209/30/2020($0.91)($0.86)+$0.05($0.86)$2.28 million$4.00 million  
8/6/20206/30/2020($1.17)($0.85)+$0.32($0.85)$2.95 million$1.73 million  
5/8/20203/31/2020($1.35)($1.22)+$0.13($1.22)$3.36 million$1.70 million  
3/16/202012/31/2019($1.05)($1.32)($0.27)($1.32)$3.54 million$3.63 million
11/4/2019Q3($0.8470)($0.95)($0.1030)($0.95)$2.03 million$4.64 million
8/8/2019Q2 2019($0.64)($0.74)($0.10)($0.74)$6.95 million$2.16 million
5/9/2019Q1($0.7830)($0.29)+$0.4930($0.29)$1.25 million$7.72 million
3/14/2019Q4($0.7460)($0.60)+$0.1460($0.60)$0.84 million$1.69 million
11/8/2018Q3($0.64)($0.60)+$0.04($0.60)$0.66 million$0.66 million
8/9/2018Q2 2018($0.77)($0.69)+$0.08($0.69)$0.62 million$0.46 million
5/10/2018Q1 2018($1.1960)($0.74)+$0.4560($0.74)$0.20 million$1.15 million
4/2/2018Q4 2017($1.77)($1.59)+$0.18($1.59)$0.40 million$0.99 million
12/14/2017Q3 2017($2.43)($36.02)($33.59)($36.02)$0.20 million$0.60 million
8/6/2013Q213$0.01+$0.01$4.20 million$4.50 million
3/7/2013Q412($0.40)($0.40)$17.00 million$15.90 million












Spero Therapeutics Earnings - Frequently Asked Questions

When is Spero Therapeutics's earnings date?

Spero Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 9th, 2023 based off last year's report dates. Learn more on SPRO's earnings history.

Did Spero Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Spero Therapeutics (NASDAQ:SPRO) reported $0.55 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.40) by $0.95. Learn more on analysts' earnings estimate vs. SPRO's actual earnings.

How much revenue does Spero Therapeutics generate each year?

Spero Therapeutics (NASDAQ:SPRO) has a recorded annual revenue of $54.00 million.

How much profit does Spero Therapeutics generate each year?

Spero Therapeutics (NASDAQ:SPRO) has a recorded net income of -$46.42 million. SPRO has generated -$0.90 earnings per share over the last four quarters.

What is Spero Therapeutics's EPS forecast for next year?

Spero Therapeutics's earnings are expected to grow from ($1.05) per share to ($1.00) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:SPRO) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -